What is the recommended management for overactive bladder in adults?

Management of Overactive Bladder in Adults

Start with behavioral therapy (bladder training, fluid optimization, weight reduction) and pelvic floor exercises as first-line treatment, then progress to β3-agonists (preferred) or antimuscarinic medications, reserving minimally invasive procedures (sacral neuromodulation, tibial nerve stimulation, or botulinum toxin injections) for inadequate responders. 1

Initial Evaluation

Look specifically for:

• Urinary urgency (the defining symptom), frequency, nocturia, and presence/absence of incontinence
• Exclude urinary tract infection through urinalysis
• Rule out urological malignancy with appropriate screening
• Measure post-void residual volume via bladder ultrasound to assess for retention
• Obtain a voiding diary (invaluable for understanding symptom patterns) 2, 3

Treatment Algorithm

First-Line: Conservative Management

• Behavioral modifications: Reduce bladder stimulants (caffeine, alcohol), optimize fluid intake
• Bladder training: Scheduled voiding with progressive interval increases
• Weight reduction if overweight
• Pelvic floor exercises

These measures have Grade I-A evidence for efficacy comparable to pharmacotherapy 4

Second-Line: Pharmacotherapy

Strongly prefer β3-agonists (mirabegron) over antimuscarinics as initial pharmacotherapy 1. This recommendation reflects critical safety concerns:

• Antimuscarinics carry dementia risk: Meta-analysis of 11 cohort studies shows association with incident dementia and Alzheimer's disease, potentially cumulative and dose-dependent 1
• Recent trends show 17% decline in anticholinergic use (2016-2018) with corresponding rise in β3-agonist prescriptions, particularly in patients >65 years 5

Antimuscarinic Contraindications/Extreme Caution:

Use antimuscarinics with extreme caution in patients with:

• Narrow-angle glaucoma
• Impaired gastric emptying (diabetes, prior abdominal surgery, narcotic use, scleroderma, hypothyroidism, Parkinson's disease, multiple sclerosis)
• History of urinary retention 1

If Antimuscarinics Are Used:

• Oxybutynin (immediate/extended release, transdermal): Most cost-effective but highest side effects
• Tolterodine, solifenacin, darifenacin, trospium: Similar objective efficacy
• Extended-release formulations or transdermal delivery reduce side effects
• Avoid dose escalation: Increases side effects without improving objective outcomes 4

Combination Therapy:

For suboptimal response to full-dose monotherapy, combine antimuscarinic with β3-agonist 6

Third-Line: Minimally Invasive Procedures

Critical paradigm shift: The 2024 AUA/SUFU guideline allows offering minimally invasive therapies without requiring trials of behavioral or pharmacologic management through shared decision-making 1. This reflects:

• Poor long-term compliance with behavioral/pharmacotherapy
• High success rates and patient satisfaction with minimally invasive options
• Recognition that treatment-naïve patients may prefer these approaches

Options (Grade A evidence):

1. Sacral neuromodulation (SNM)
2. Tibial nerve stimulation (percutaneous PTNS or implantable)
3. Intradetrusor botulinum toxin A injection (100 units)
   • Critical caveat: Patient must be able and willing to perform intermittent self-catheterization (~5% will require this) 3

All three reduce voiding frequency, nocturia, urgency episodes, and incontinence episodes 1

Third-line therapy utilization nearly doubled from 2013-2018 (9 to 17 procedures per 1000 OAB patients), indicating growing acceptance 5

Common Pitfalls

1. Cognitive impairment risk: Always discuss dementia association when prescribing antimuscarinics for chronic use, especially in elderly patients 1

2. Patient expectations: OAB is chronic with low cure rates; manage expectations for symptom improvement rather than cure 2

3. Premature discontinuation: Continuation rates for antimuscarinics are low; provide education on realistic efficacy and treatment duration 4

4. Urodynamic testing: Reserve for refractory cases after initial therapy failure, not for initial diagnosis 2, 3

5. Estrogen therapy: Vaginal estrogen may provide subjective improvement, but oral/transdermal estrogen is no better than placebo 4

When to Refer to Specialist

• Inadequate response to pharmacotherapy
• Consideration of minimally invasive procedures
• Hematuria, pelvic mass, pelvic pain, or neurological disease present
• Need for urodynamic testing or cystourethroscopy 2, 7